Your email has been successfully added to our mailing list.

×
0 -0.00060422960725085 -0.00120845921450148 0.00483383685800615 0.000906344410876167 -0.00966767371601209 -0.0015105740181268 -0.0163141993957704
Stock impact report

NewAmsterdam Pharma's Cholesterol Drug To See Blockbuster Sales, Bullish Analyst Sees Massive Upside [Yahoo! Finance]

NewAmsterdam Pharma Company N.V. - Ordinary Shares (NAMS) 
Company Research Source: Yahoo! Finance
In July, NewAmsterdam Pharma released topline data from the Phase 3 BROOKLYN trial, the first of four studies in NewAmsterdam's pivotal clinical development program, to evaluate obicetrapib in adult patients with heterozygous familial hypercholesterolemia whose LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy The study achieved the primary endpoint of LS mean reduction of in LDL-C on top of maximally tolerated lipid-modifying therapies at day 84 with a statistically significant reduction sustained at day 365. Also Read: Analyst Confident In NewAmsterdam Pharma's Cholesterol Drug Despite Mixed Reactions To Study Results Obicetrapib lowered LDL-C by 36.3% on day 84 and 41.5% on day 365, compared to the placebo. The observed reductions in other biomarkers met statistical significance. Needham highlights that Obicetrapib stands out from previous CETP inhibitors due to its lack of associated issues. The upcoming phase 3 trial result Show less Read more
Impact Snapshot
Event Time:
NAMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for NAMS alerts
Opt-in for
NAMS alerts

from News Quantified
Opt-in for
NAMS alerts

from News Quantified